. 2019 Dec 9;47(4):967–979. doi: 10.1007/s00259-019-04586-z

Table 1.

Objectives and endpoints

Objectives	Endpoints
Primary
To determine the utility of [¹⁸F]FB-A20FMDV2 to quantify αvβ6 availability in healthy, IPF and CTD-ILD participants	Uptake and distribution of [¹⁸F]FB-A20FMDV2 in organs of interest (volume of distribution [V_T], and/or standardised uptake values [SUV]).
Secondary
To compare [¹⁸F]FB-A20FMDV2 uptake in areas of the lungs with varying degrees of fibrosis as determined by high resolution computed tomography (HRCT).	Qualitative assessment of the relationship between the distribution of fibrosis in the lungs from IPF and CTD-ILD participants and the uptake of [¹⁸F]FB-A20FMDV2.
To compare [¹⁸F]FB-A20FMDV2 uptake in IPF and CTD-ILD lungs versus healthy lungs.	Volume of distribution (V_T), and/or standardised uptake values (SUV) in IPF and ILD vs healthy lungs.
To determine the reproducibility of [¹⁸F]FB-A20FMDV2 uptake in IPF and CTD-ILD participant lungs.	Test/re-test variability of volume of distribution (V_T), and/or standardised uptake values (SUV).